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Cannabinoid Modulation of Microglial Activation in Multiple Sclerosis 
Natalie Shea Lemons 
Multiple Sclerosis (MS) is a neurodegenerative disease that is estimated to affect 400,000 
Americans. There is no cure for MS and some treatments at this point are toxic to patients. Dr. Lori 
Hensley's lab is researching two drugs that could potentially be used to treat MS without toxic effects. 
Previous work in the lab shows ajulemic acid, a synthetic molecule similar to metabolites from the 
cannabis plant, selectively suppresses markers of the inflammatory response. 1 worked on the 
mechanism of ajulemic acid's action by investigating the roles of several candidate receptors in 
mediating these observed effects. 
Introduction: 
Immune Response 
The human body under normal circumstances has an efficient immune system that protects and 
heals the body. There are two main divisions of the immune response, innate immunity and the 
adaptive specific immune response. Innate immunity is a constant part of the body that has a defense 
mechanism against foreign cells such as pathogens. It is not specific to one type of pathogen; 
therefore, it is usually followed by the adaptive specific immune response. Adaptive immunity is 
started by the recognition of an antigen by a lymphocyte. An antigen is a marker of a cell that binds 
with antibodies. It marks the cell as foreign or self. There are two types of lymphocytes that are active 
during the adaptive response. First, B lymphocytes, which after a process, become plasma cells are 
responsible for secreting antibodies. Second, T lymphocytes are responsible for the actual recognition 
and killing of foreign cells(Charles A. Janeway and Travers 1994). 
In normal production of lymphocytes, these cells go through a process called self tolerance. 
Self tolerance is the ability not to respond to self antigens. This occurs in the developmental stages of 
lymphocyte production. If during lymphocyte development, the lymphocyte binds to a self antigen, it 
is programmed to die. In autoimmune diseases like MS, something has gone wrong. According to 
Janeway and Travers, an autoimmune response occurs when a "specific adaptive immune response is 
mounted against self." Specifically, in autoimmune diseases, T cells recognize the self cell as foreign 
and elicit a response accordingly(Charles A. Janeway and Travers 1994). 
Microglia 
Microglia are cells in the central nervous system (CNS) that act as part of the immune system of 
the body. They are responsible for removing waste from the CNS(Kalat 2007). For this function to 
occur, they are able to develop into phagocytic cells(Young, Lowe et al. 2006). Phagoctyic cells ingest 
and destroy foreign material. Microglia normally control the number ofT cells in the CNS and are 
involved in the perpetration and termination of the inflammatory response. This process is defective in 
MS patients and accounts for the chronic inflammation caused by the T cell presence. In MS, 
microglia are found in the lesions that are actively demylinating(Sanders and DeKeyser 2007). Our 
experimental studies were performed on highly aggressive proliferating immortalized (HAPI) 
microglia cells. This cell line has been immortalized, allowing the division of cells to continue without 
having to use new cells for each experiment. Because HAPI cells do have some differences from 
primary microglia cells, we duplicated our experiments in primary microglia. HAPI cells do not 
produce the cytokine IL1-B that is an important cytokine in the study of the inflammatory response. 
Most of the data presented in this text will be from HAPI microglia cells with a few exceptions. 
Astrocytes 
Astrocytes are star-shaped cells in the brain that help with the synchronizing of axons(Kalat 
2007). They have several roles including mechanical support and transfer of metabolites. For our 
2 
study, the two main functions of astrocytes are the production of the blood-brain barrier and their role 
in CNS tissue repair after damage(Y oung. Lowe et al. 2006). Due to these roles, it is thought that 
when astrocytes are activated in the inflammatory response, they create leakage in the blood-brain 
barrier allowing the self-reactive T cells to get into the brain. 
Multiple Sclerosis 
Multiple Sclerosis is an autoimmune disease. In MS, the central nervous system (CNS) is the 
site of the problem. Autoreactive T cells attack the myelin sheath of neurons, and inflammatory 
cytokines are released by these T cells as well as microglia and astrocytes (Lori Hensley 2006). 
Cytokines are proteins produced by one cell that affect other cellular behavior. Cytokines released by T 
cells and other lymphocytes are called interleukins (IL). Interleukins are released and act on cells that 
have been identified as foreign and program them for apoptosis, or cell death( Charles A. Janeway and 
Travers 1994 ). 
The myelin that is lost through this autoimmune attack is replaced by sclerosis or scar tissue. 
The destruction of the myelin affects the ability of the nerve fibers to conduct impulses throughout the 
CNS(2006). The inability of the myelin to conduct impulses is what causes the symptoms of MS. It is 
very difficult to give a list of symptoms because they vary from situation to situation. The symptoms 
include bladder and bowel dysfunction; problems with memory, attention, and problem solving; 
vertigo; dizziness; emotional changes; fatigue; balance and coordination problems; numbness; pain; 
spasticity; sexual dysfunction; vision problems; headache; hearing loss; itching; seizing; speech 
disorders and tremors(2006). 
Because ofthe wide range of symptoms, MS is difficult to diagnose. What makes it even 
harder to diagnose is that there is not just one specific diagnostic test. Despite the difference in 
diagnostic tools, they all must confirm two signs for a positive MS diagnosis. First, there must be signs 
of disease in different parts of the nervous system. Second, the patient must have experienced at least 
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two flare-ups of symptoms. A complete medical history is the first step in starting to diagnose a patient 
because there are some genetic factors involved in the disease. The next step is determining the level at 
which the nervous system is functioning. Three different tests may be used to determine this level. A 
magnetic resonance imaging (MRl) is used to view the brain and look for lesions(2006). There are two 
problems with this; not everyone with MS has lesions and not all patients can have an MRI done(Lori 
Hensley 2006) . An evoked potential test is also used. It measures the level at which the nervous 
system is working and can show demyelination by measuring the response time and accuracy of a 
person ·s nervous system to certain stimuli. The third test used is a spinal tap, otherwise known as a 
lumbar puncture(2006) . The spinal tap is specifically looking for an increase in immune response 
proteins(Lori Hensley 2006). 
Once a patient is diagnosed with MS, a physician determines which of the four types of MS 
they have. At the time of initial diagnosis, the most common form is relapsing-remitting. The patient 
with this type has periods of flare-ups, also called relapses, attacks, or exacerbations, where the 
symptoms worsen, but they also have times of partial or complete recovery. A rare form of MS is the 
primary-progressive. These patients have a continuing worsening of their disease from the onset. Half 
of the people with relapsing-remitting MS will develop the third type, secondary progressive, within 
ten years. This form combines relapsing-remitting and primary progressive. The patient has an initial 
period of relapsing-remitting, and then the disease gets steadily worse. The fourth and final form is 
progressive-relapsing. Patients with this form have a steadily worsening disease, but also have relapses 
with or without recovery(2006). 
With such a wide range of symptoms, diagnostic tools. and forms, there is no cure and limited 
treatment. The goal of the treatment is to make the quality of life better by treating the symptoms and 
slowing the progression of the disease. Different types of therapy and drugs are used. The drug 
treatments approved by the FDA are Betaseron, Avonex, Rebif, Tysabri, Copaxone and Novantrone. 
Novantrone is the company that produces mitoxantrone, which is a form of chemotherapy(2006). The 
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problem with mitoxantrone is not only does it have beneficial effects on the patient but negative as 
well(Lori Hensley 2006). The major beneficial effect is the progression of demyelination is 
slowed(Tull 2006). The primary negative effect of mitoxantrone is it can only be used for the 
relapsing-remitting and secondary progressive forms of MS. Also, patients can only take it for two 
years of their lives due to its cardiotoxic affects. The specific cardiotoxic affects include a higher 
possibility ofthe patient developing congestive heart failure(Goodin, Amason et al. 2003). 
Mitoxantrone is the only treatment currently available for progressive forms of the disease. 
Cannabis 
One drug that has been debated for medical use for years is cannabis, otherwise known as 
marijuana. THC (tetrahydrocannabinol) is a psychoactive drug produced from the cured flowers and 
the trichomes of the female cannabis plant. THC has both psychoactive and medicinal properties. 
Cannabis is usually taken in by either smoking or ingestion. Cannabis has been shown to help in limb 
muscle spasms, migraines, pain, cramps, asthma, and several other symptoms of diseases(Baker, Pryce 
et al. 2003). One trial showed improvement in walking and patient perception of spasticity, muscle 
spasms, pain, and sleep. Although some of the tests results did not show as great a change as hoped, 
they did support the patient's claims of improvement. It seemed the longer the trial went, the better the 
drug worked. The same trial also showed reduction in relapses that required hospital stays(Zaj icek, 
Sanders et al. 2005). One source showed that during a medical trial using cannabis on MS patients, the 
cytokine levels, specifically interfeuron-y, interleukin-1 0, and interleukin-12, were measured. 
However, no differences were found between treated and control patients(Katona, Kaminski et al. 
2005). Cytokine levels reflect the amount of inflammation in the CNS. Due to the nature of cannabis, 
there are not as many trials being run as there are on other drugs. 
The medicinal use of cannabis has been around for thousands of years, but came to North 
America in the late 1800s or early 1900s. Since its entrance into the medical scene, cannabis has been 
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debated. The government fears the use of it for medicinal purposes will spiral out of control, but they 
too have gone back and forth on the use of cannabis. The government first dealt with this issue in 1854 
when cannabis was on the US Dispensary lists as a remedy for neuralgia, depression, hemorrhage, pain 
relief, and muscle spasm. In 1870 it was on the list of US Pharmacopoeia as a medicine. The 
government's standing shifted in August of 1937 with the Marijuana Tax Act that put a tax on 
transactions dealing with marijuana. This act did not outlaw marijuana, but made it too expensive for 
physicians to prescribe to their patients. In 1941, cannabis was removed from the US Pharmacopoeia 
list. However, the Common Law Doctrine of Necessity gave Robert Randall the right to use marijuana 
to treat his glaucoma. In 1978, two years after Randall was given this right, the National Institute of 
Drug Abuse (NIDA) started. The NIDA allowed patients to receive marijuana from the government. 
However, this policy was reversed in 1992. Another setback to the medicinal use of cannabis includes 
former Presidents Gerald Ford, Jimmy Carter, and George Bush publishing letters in 1996 opposing 
the legalization of marijuana for the reason it would "undermine youth drug prevention 
programs'"(History). The above government actions are just a few of the actions that have taken place 
involving the medicinal legalization of cannabis. Other debates about cannabis include the morality of 
its use and the side effects that seem to occur from use over time. 
Ajulemic Acid 
Because cannabis is such a debated drug, researchers are currently looking for a drug that has 
similar effects but is less controversial. One of these drugs is ajulemic acid (AJA). AJA is a 
cannabinoid-derived structure that has no evidence of the psychotropic actions common with 
cannabis(Burstein 2005). In other words, it should have the positive effects of cannabis without the 
negative. 
AJA when tested with rats showed relief of pain and inflammation. It also prevented 
destruction of inflamed joints. Because AJA does not have the psychoactive properties of cannabis, it 
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has low dependence liability. Rats were given AJA for 14 days and then observed for opiate 
withdrawal effects; none were observed. After the 14-day trial, tests were run for the level of 
carcinogenicity. AJA was found to have none(Burstein 2005). 
Another problem that most anti-inflammatory medications have is production of ulcers. Rats 
given high doses of AJA (up to 1000 mg/kg) had no ulcers form; this could be due to the lack of 
inhibition of cyclooxygenase-1 (Cox-l) inAJA. Cox-1 is a protein that acts as an enzyme to help 
protect the inner stomach. It does this by speeding up production of chemical messengers called 
prostaglandins that work in cells responsible for inflammation to protect them. After tested in rats, a 
phase 2 human trial was run with chronic, neuropathic pain patients, and the data supported AJA as a 
safe, well-tolerated drug with no adverse effects(Burstein 2005). The only side effects observed were 
dry mouth and tiredness(Burstein, Karst et al. 2004). 
In theory, AJA would be the answer to everyone 's problems with MS treatment. It would help 
MS patients with symptoms and progression without a time limit on usage. Christians and people with 
moral dilemmas should have no problem with AJA because it does not have psychoactive effects, 
which would also relieve the fears of the message being sent to young people. Also, the government 
would be able to approve the drug without fear of it being a gateway drug to other illegal substances. 
Materials and Methods 
Basic Procedure: 
Throughout my research, the protocol of experiments changed depending on the type of 
treatment being tested on our HAPI cells, but the basic process was the same. After growing cells in 
flasks for several days, they were placed into well plates for a day to adhere to the bottom of the plate. 
Once the cells adhered, treatment was performed. The treatment usually started with the antagonist of 
choice, followed by the agonist of choice 30 minutes later. Once the agonist and antagonist had time to 
react and bind to the receptor sites, lipopolysaccharide (LPS) was added to induce the inflammatory 
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response from the cells. The cells were incubated for a day and analyses were performed. The first 
analysis ran was a nitrite assay to determine the level of nitric oxide released by the cells. The higher 
the nitrite levels, the more inflammatory response the cells experienced. MTT (3-(4,5-
dimethylthiazone-2yl)-2,5-diphenyltetrazolium bromide) viability assay was run in addition to the 
nitrite assay as an internal control. If the cells showed similar viability in all experimental conditions, 
then our experimental data was accurate, but if the cells varied significantly in viability, our data was 
skewed. Both the nitrite and MTT analyses were inexpensive and easy to perform; therefore, they were 
done first. If good results were obtained, a number of ELlS As could be performed with other cytokines 
such as IL-6, TNF-a, MCP-1, IL-lB and IL-1 2p40. 
Primary Cell Culture 
Cerebral cortices from one- to three-day-old C57BL/6 mice were excised, meninges removed, 
and cortices minced into small pieces. Cells were separated by trypsinization followed by trituration of 
cortical tissue. The cell suspension was filtered through a 70-J..lm cell strainer to remove debris. Cells 
were centrifuged at 153xg for 5 min at 4 °C, resuspended in Dulbecco's modification of Eagle's 
medium (DMEM) containing 10% FBS, 1.4 mM 1-glutamine. 100 U/mL penicillin, 0.1 mg/mL 
streptomycin, OPI medium supplement, and 0.5 ng/mL recombinant mouse GM-CSF, and plated into 
tissue culture flasks. Cells were allowed to grow to confluence (7- 10 days) at 37 °C/5% C02. Flasks 
were then shaken overnight (200 rpm at 37 °C) in a temperature-controlled shaker to loosen microglia 
and oligodendrocytes from the more adherent astrocytes. These less adherent cells were plated for 2-3 
hours and then lightly shaken to separate oligodendrocytes from the more adherent microglia. 
Microglia were seeded in 96-well plates ( 4 x I 04 cells/well) and incubated overnight at 3 7 °C/5% C02. 
Astrocytes were recovered by trypsinization and seeded into 96-well plates ( I x 105 cells/well). 
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Cell Culture 
HAPJ microglia cells were cultured at 3TC and 5.0% C02 in DMEM with Earle's salts 
containing a final concentration of 10% fetal bovine serum and 1.38 mM L-glutamine. 
Determination ofCell Viability 
Cell viability was measured with an MTT assay, measuring mitochondrial activity. MTT 
solution was prepared by diluting MTT 1 :50 with culture medium. Cell culture media was removed 
from cells and replaced with 500 ~1 MTT solution and incubated at 37 ·c for one hour. MTT solution 
was removed and cells were lysed by adding 500 J.!l DMSO/well. Plates were rocked for 30 minutes 
and read on a plate reader at 570 nm. 
Determination of Nitrite Production 
Cells were plated in a 24-well plate at 3.68 x 105 cells/well and incubated for 24 hours before 
treatment with the antagonist of interest. Cells were then incubated for 30 minutes. and the agonist of 
interest was added. Cells were then incubated an additional l-4 hours before inducing activation of 
HAPI microglial cells with LPS. Media was harvested from wells after 24 hours; 50 J.!l of each sample 
was added to a 96-well plate with 50 f..ll Gries reagent and read on a plate reader at 550 nm. 
ELISA Assays 
Media was harvested from cells treated as above and used in enzyme-linked immunosorbent 
assays (ELISA) according to manufacturer's recommendations (BD Biosciences-Pharmingen). 
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Results 
Prior to my research, Dr. Hensley's lab found AJA does suppress the inflammatory response of 
cultured microglia without being toxic to the cells. This finding was determined by inducing an 
inflammatory response, using LPS (a substance found in bacterial cell walls) in microglial cells that 
were pre-treated with AJA. Figure 1 shows the MTT assay illustrating that AJA was not toxic to the 
cells. AJA has shown to be a specific suppressor in the fact that it suppresses some cytokines, doesn't 
suppress some, and enhances others. In the HAPI system, AJA suppressed nitric oxide (figure 2). In 
the primary microglia, AJA showed signs of suppressing MCP-1 and IL-l B (figure 3). MCP-1 in 
HAPI cells showed no suppression and there was a small hint of enhancement (figure 4). IL-JB is a 
cytokine that is not released by HAPI cells and therefore must be tested in primary microglia. It is 
suppressed in both primary astrocytes and microglia. In the HAPI system, AJA does not suppress IL-6 
(figure 5). AJA showed no effect on the response ofTNF- a in HAPI cells (figure 6). but showed 
enhancement in primary astrocytes (data not shown). Since TNF- a is needed for repair this could be a 
good sign that AJA suppresses the worst cytokines and enhance the cytokines with repair mechanisms. 
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FIG 1. Ajulemic acid does not affect the viability of HAPI microglial cells induced by LPS. Cells 
were pre-treated for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at 
0.5 mg/ml and 24 hours later cell viability was determined. Values represent the average for triplicate 






FIG 2. Ajulemic acid inhibits LPS induction of nitrite in HAPI microglia cells. Cells were pre-
treated for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at 0.5 mg/ml and 
24 hours later the concentration of nitrite in the culture media was determined. Values represent the 
average for triplicate cultures and standard errors are indicated. Comparisons were made to LPS-only 










FIG 3. Ajulemic acid inhibits LPS induction of ILl-B in primary microglia. Cells were pre-treated 
for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at a final concentration 
of 0.5 mg/ml and 24 hours later the concentration ofiL-6 in the culture media was determined. Values 
represent the average for triplicate cultures and standard errors are indicated. Comparisons were made 











FIG 4. Ajulemic Acid shows no inhibition of LPS induction of MCP-1 in HAPI microglia cells. 
Cells were pre-treated for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at 
a final concentration of 0.5mg/ml and 24 hours later the concentration of MCP-1 in the culture media 
was determined. Values represent the average for triplicate cultures and standard errors are indicated. 











FIG 5. Ajulemic acid does not inhibit LPS induction of IL-6 in HAPI microglia cells. Cells were 
pre-treated for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at a final 
concentration of 0.5 mg/ml and 24 hours later the concentration ofiL-6 in the culture media was 
determined. Values represent the average for triplicate cultures and standard errors are indicated. 
Comparisons were made to LPS-only treated cultures. Asterisks indicate stati stical significance of 
p<.05. 











FIG 6. Ajulemic acid shows no effect on LPS induction ofTNF- a in HAPI microglia cells. Cells 
were pre-treated for 4 hours with the indicated concentrations of ajulemic acid. LPS was added at a 
final concentration of0.5 mg/ml and 24 hours later the concentration ofTNF- a in the culture media 
was determined. Values represent the average for triplicate cultures and standard errors are indicated. 
Comparisons were made to LPS-only treated cultures. Asterisks indicate statistical significance of 
p<.05. AJA shows enhancement ofTNF - a in primary astrocytes (data not shown). 
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Based on these findings, the search for how AJA works began. When I started working on AJA, 
we knew that AJA worked to selectively suppress the inflammatory response, but we wanted to know 
how or through what receptor. Our hypothesis was thatAJA was working through the PPAR- y 
receptor. AJA has been shown to bind to the ligand domain of the human PPAR- yin previous 
experiments(Liu, Li et al. 2003; Ambrosio, Dias et al. 2007). The problem with this hypothesis is that 
it is very difficult to test this specific receptor. The first item on the agenda was to rule out the 
cannabinoid receptors, which would give more support to the hypothesis. There are two cannabinoid 
receptors, CB 1 and CB2. CB l is known to be the receptor mediating psychotropic effects while CB2 is 
thought to mediate immune responses; therefore, we wanted to look at CB2. We had to set up a 
positive control using known CB2 agonists and antagonist, which would be used to compare AJA's 
effects on the cells. Agonists are compounds that are known to bind to and activate the specific 
receptor being examined. Antagonists are compounds that are known to bind to the same receptor 
competitively and block the effects ofthe agonist. Three different agonists (L-759,633, GW 405,833, 
CP 55,940) were used, but none behaved in a manner that would serve as a good positive control. One 
ofthe systems we tried was the agonist L-759,633 and the antagonistAM630. After the concentration 
was found at which L-759,633 was effective to suppress LPS-induced nitrite release (figure 7), it was 
tested with AM630 concentrations (figure 8). The problem with these concentrations was that AM630 
was found to be toxic at concentrations above 10 }!M and L-759 ,63 3 was not effective until 120 }J.M. 
Because the agonist's concentration was so much larger than the antagonist concentration, the agonists 
overwhelmed and bound to the sites despite the presence of the antagonist. A positive control was 
needed for comparative purposes. If we merely used the CB2 antagonist AM630 with AJA and did not 
abrogate the suppression of nitrite we normally observed, we could assume these effects were not 
mediated by CB2. However, it could be that no effect was seen because something in the design of our 






FIG 7. Concentrations of L-759,633 were tested to find the minimal concentration necessary for 
suppression of LPS-induced nitrite release. Cells were pre-treated for 3 hours with the indicated 
concentrations of L-759,633. LPS was added at a final concentration of 1 ~-tg/ml and 24 hours later the 
concentration of nitrite in the culture media was determined. Values represent the average for triplicate 
cultures and standard errors are indicated. Comparisons were made to LPS-only treated cultures. 
Asterisks indicate statistical significance of p<.05. Later experiments showed a dosage of 120 ~-tM to 
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FIG 8. AM630 did not abrogate the suppression effects of L-759,633. Cells were pre-treated for 30 
minutes with the indicated concentrations of AM630 before adding 120 uM of L-759,633 for an 
additional 3 hours. LPS was added at a final concentration of 1 11g/ml and 24 hours later the 
concentration of nitrite in the culture media was determined. Values represent the average for triplicate 
cultures and standard errors are indicated. Comparisons were made to LPS-only treated cultures. 
Asterisks indicate statistical significance of p<.OS. 
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One problem that was brought to our attention was that lipopolysaccharide (LPS), which we 
used to induce the inflammatory response in our cells may down-regulate the CB2 receptor(Lee, 
Newton et al. 2002). If this was true, it would explain why we were not able to set up a positive 
control with LPS. We switched to using TNF-a and IFN-y to induce the inflammatory response, but 
the results showed no difference between it and LPS. We would have expected that the TNF- a and 
IFN- y results would show more suppression of cytokines ifLPS down-regulated CB2 and our effects 






FIG 9. TNF- a and IFN- y induced inflammatory response instead ofLPS induction did not alter 
suppression of nitrite by AJA. Cells were pre-treated for 3 hours with the indicated concentrations of 
AJA. TNF- a and IFN- y was added at a final concentration of 100 units/ml ofiFN - y and 500 
units/ml ofTNF- a and 24 hours later the concentration of nitrite in the culture media was determined. 
Values represent the average for triplicate cultures and standard errors are indicated. Comparisons were 
made to TNF- a and IFN- y -only treated cultures. 
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Discussion 
Despite the struggles and disappointments of our positive control testing, we still have some 
support for AJA working through PPAR- y. CB receptors are known to work at nanomolar amounts, 
and we have only seen suppression at micromolar amounts. This supports that our effects were neither 
CB 1 nor CB2 mediated. A problem mentioned earlier, about LPS down-regulating CB2, was not 
supported by our data because when TNF- a and IFN- y were used to induce the inflammatory response 
there was no increase in suppression by AJA seen. Although none of these results were what we 
expected, they still support our original idea. 
The research field for cannabinoid derivatives is still wide open. For example, ajulemic acid is 
currently being used to kill neural derived cells with anti-tumor properties. This could lead to alternate 
treatments or cures for some types of cancer. AJA is also being used in clinical trials for neuropathic 
pain and muscle spasms. Canabidiol, another cannabinoid, is currently being used in pain trials and is 
showing some of the same positive effects of AJA(Rog, Nurmikko et al. 2007). Other cannabinoid 
receptors such as GPR55 are being found as well(Baker, Pryce et at. 2006). We may not have been 
able to find the receptor AJA mediated its response through because it has not yet been found. 
The good news forMS patients is that research is continuing and expanding. Currently in the 
lab, research is still being done on AJA and another potential treatment, resveratrol. Research is being 
conducted on the neuroprotection capabilities of these drugs. Although it might seem our research 
ended the opposite of what we expected, it did not end hopelessly. Research is an ongoing process 
where all experiments move us one step closer to understanding the disease and potential treatments. 
The more knowledge that researchers have, the more likely we will see advancement in the treatment 
of multiple sclerosis. 
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